Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. (Q27853078)
Jump to navigation
Jump to search
scientific article
- Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. |
scientific article |
|
Statements
2 references
Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo (English)
C L Schwab
S Bellone
D P English
D M Roque
E Cocco
I Bortolomai
E Ratner
D-A Silasi
M Azodi
P E Schwartz
T J Rutherford
A D Santin
30 September 2014
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
2 references
2 references